✦ LIBER ✦

GEMOX-R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma: a phase II study

✍ Scribed by Andrés López; Antonio Gutiérrez; Andrés Palacios; Isabel Blancas; Maite Navarrete; Miguel Morey; Antonia Perelló; Jesús Alarcón; Jordi Martínez; José Rodríguez

Book ID: 114794327
Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 133 KB
Volume: 80
Category: Article
ISSN: 0902-4441
DOI: 10.1111/j.1600-0609.2007.00996.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Gemcitabine, cisplatin and methylprednis

Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma

✍ Ng, M; Waters, J; Cunningham, D; Chau, I; Horwich, A; Hill, M; Norman, A R; Woth 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 107 KB

Phase II study of a salvage regimen usin

Phase II study of a salvage regimen using cyclophosphamide, high-dose cytarabine, dexamethasone, etoposide, and rituximab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma

✍ Yasuhiro Oki; Michinori Ogura; Harumi Kato; Ako Kikuchi; Hirofumi Taji; Yoshitoy 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 107 KB

Phase II study of the CPT-11, mitoxantro

Phase II study of the CPT-11, mitoxantrone and dexamethasone regimen in combination with rituximab in elderly patients with relapsed diffuse large B-cell lymphoma

✍ Nozomi Niitsu; Mika Kohuri; Masaaki Higashihara; Masami Bessho 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 178 KB

R-ESHAP plus pegfilgrastim as an effecti

R-ESHAP plus pegfilgrastim as an effective peripheral stem cell mobilization regimen for autologous stem-cell transplantation in patients with relapsed/refractory diffuse large B-cell lymphoma

✍ Montoro, Juan; Andreola, Giovanna; Gardellini, Angelo; Babic, Aleksandra; Negri, 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 406 KB

A phase II study of the survivin suppres

A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma

✍ Bruce D. Cheson; Nancy L. Bartlett; Julie M. Vose; Andres Lopez-Hernandez; Amand 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 232 KB

Dose-adjusted EPOCH plus rituximab is an

Dose-adjusted EPOCH plus rituximab is an effective regimen in patients with poor-prognostic untreated diffuse large B-cell lymphoma: results from a prospective observational study

✍ Julio García-Suárez; Helena Bañas; Ignacio Arribas; Dunia De Miguel; Teresa Pasc 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 506 KB